Dr. Mikhail Blagosklonny is an aging and cancer researcher. He is also the Professor of Oncology at Roswell Park Cancer Institute. Dr. Blagosklonny attended the First Pavlov State Medical University of St. Petersburg where he graduated with his M.D. and Ph.D. degrees in experimental medicine and cardiology. When he first came to the United States he was an Associate Professor of Medicine at the New York Medical College located in Valhalla, New York. From 2002 to 2009 he worked at the Ordway Research Institute where he was a Senior Scientist.
The cancer research that Dr. Mikhail Blagosklonny conducts involves molecular and cellular biology. His research is focused on devising new anti-cancer methods that make use of cancer cell cycling and drug resistance in order to protect normal cells. He uses this same approach in his research about aging. Dr. Blagosklonny is one of the most ardent voices for researching the widely used cancer drug Rapamycin as a way to extend life and it plays a large role in his research at the Roswell Park Cancer Institute. Visit ResearchGate to know more about Mikhail’s latest work.
In addition his research and teaching, Dr. Mikhail Blagosklonny is also an editor of several peer-reviewed medical journals. His most popular medical journal, where he is a co-editor-in-chief, is Oncotarget. His mission at Oncotarget is to make published research widely available and to do so the journal is free-access. Another part of his mission at Oncotarget is to eliminate the separation between different fields of medicine in order to encourage cross-disciplinary communication and collaboration.
Among the other peer-reviewed medical journals that Dr. Blagosklonny edits are Oncoscience, Aging, and Cell Cycle. He is an Associate Editor for other journals including Autophagy, The American Journal of Pathology, Cell Death and Differentation, and Cancer Biology & Therapy among others.
Dr. Mikhael Blagosklonny has also published a great amount of his own research in peer-reviewed medical journals. He has written over 300 papers that have been cited by other researchers over 25,000 times. Read more about Mikhail at LinkedIn